Abstract
Reasons to purchase
The UK Department of Health (DoH) has introduced a key policy concerning the
reissuing of patients own pharmaceuticals on admission into hospital,
determining that this will save money and improve quality of care.
This report examines and questions the introduced DoH policy to show how it
may represent a significant challenge to the integrity of the Chain of Trust,
which offers protection to both manufacturers and patients.
Report scope
- What is the pharmaceutical chain of trust?
- The introduced DoH policy on re-issuing medicines
- Questions regarding the introduced policy
- How does the introduced policy of selected re-issuing impact upon the
basis of pharmaceutical regulation in the UK?
- Is cost-saving a valid (and ethical) basis for revising pharmaceutical
regulation?
- Re-issuing in the absence of enabling legislation
This report examines and questions the introduced DoH policy on reissuing
medicines in the NHS to show how it may represent a significant challenge to
the integrity of the Chain of Trust, which offers protection to both
manufacturers and patients.
Who should buy the report
This report is essential reading for:
- Pharmaceutical manufacturers either manufacturing in or supplying to the UK
- Product developers
- Decision makers involved in drug safety
- Policy makers
- Charities involved in donated pharmaceuticals
- Companies and institutions considering donating pharmaceuticals
| 
View Cart
